JAK2 and myeloproliferative disorder: For example, it is known now in MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) that the JAK2 V617F mutation drives the thrombocytosis while the SF3B1 mutation drives the increased ring sideroblasts [7].